Ahn Jaehyun, Shin Christopher, Kim Yeo Song, Park Jae-Sung, Jeun Sin-Soo, Ahn Stephen
College of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Brain Tumor Res Treat. 2022 Jul;10(3):135-143. doi: 10.14791/btrt.2022.0010.
Over the last two decades, numerous studies have investigated the presence of human cytomegalovirus (CMV) within glioblastoma or gliomas; however, the results are severely conflicting. While a few researchers have suggested the potential benefits of cytotoxic T lymphocyte or dendritic cell-based vaccines for recurrent or newly diagnosed glioblastoma patients, several studies did not at all agree with the existence of CMV in glioblastoma cells. In this review, we summarized the conflicting results and issues about the detection of CMV in glioblastoma or glioma patients. We also provided the clinical data of published and unpublished clinical trials using CMV-specific immunotherapy for glioblastomas.
在过去二十年中，众多研究调查了胶质母细胞瘤或胶质瘤中人类巨细胞病毒（CMV）的存在情况；然而，结果存在严重分歧。虽然一些研究人员提出了基于细胞毒性T淋巴细胞或树突状细胞的疫苗对复发性或新诊断的胶质母细胞瘤患者的潜在益处，但一些研究完全不同意胶质母细胞瘤细胞中存在CMV。在本综述中，我们总结了关于胶质母细胞瘤或胶质瘤患者中CMV检测的相互矛盾的结果和问题。我们还提供了使用CMV特异性免疫疗法治疗胶质母细胞瘤的已发表和未发表临床试验的临床数据。
